{"id":"W2761396813","doi":"10.1200/jco.2017.35.15_suppl.tps4136","title":"Integrate II: A randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC)—An international study organized by the Australasian Gastrointestinal Trials Group (AGITG).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Regorafenib; Internal medicine; Clinical endpoint; Placebo; Ramucirumab; Hazard ratio; Bevacizumab; Population; Oncology; Adverse effect; Refractory (planetary science); Surrogate endpoint; Phases of clinical research; Cancer; Clinical trial; Chemotherapy; Colorectal cancer; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003181906,0.003361123,0.004658299,0.0007841693,0.000650747,0.001431996,0.001683874,0.002878057,0.01184802],"category_scores_gemma":[0.002115619,0.001168416,0.002584935,0.0007031675,0.001822858,0.001575669,0.0007654428,0.003982855,0.002008259],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008690887,"about_ca_system_score_gemma":0.002109424,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001175559,"about_ca_topic_score_gemma":0.003386153,"domain_scores_codex":[0.999189,0.0003968709,0.00005122476,0.0001484737,0.00006541314,0.0001491048],"domain_scores_gemma":[0.9988966,0.0001919062,0.000258755,0.0001188962,0.00008383298,0.0004500439],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9777776,0.01109494,0.0002799794,0.0005651952,0.0004685758,0.00002767008,0.00004142654,0.0001846951,0.002531189,0.00007609284,0.000844896,0.006107776],"study_design_scores_gemma":[0.9617929,0.03692312,0.0004777304,0.00001311293,0.0001302292,0.0000120356,0.000008845578,0.00007709149,0.0001277469,0.00004808883,0.0003820912,0.000007036992],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9392358,0.006843118,0.001715742,0.001533312,0.001499266,0.03841366,0.005787013,0.0006561973,0.004315972],"genre_scores_gemma":[0.9009447,0.005778839,0.005765239,0.004912957,0.001971861,0.06367041,0.005653994,0.0001400574,0.01116198],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01184802,"threshold_uncertainty_score":0.0396356,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1891700578129553,"score_gpt":0.5260266435446584,"score_spread":0.3368565857317031,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}